Pep19-2.5

OC(CNC([C@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC(CNC([C@H](CCCCN)NC([C@@H](NC([C@H](CCCCN)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CS)NC(CN)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)CC5=CC=CC=C5)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)CC8=CC=CC=C8)=O)=O)=O)=O)CC9=CC=CC=C9)=O)CC%10=CNC%11=CC=CC=C%10%11)=O)=O)=O)=O

[1]Heinbockel L, et al. Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep19-2.5. Front Immunol. 2018 Jul 26;9:1704. |[2]Bárcena-Varela S, et al. Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits. Exp Mol Med. 2017 Jun 16;49 (6) :e345. |[3]Jannadi H, et al. Antimicrobial peptides Pep19-2.5 and Pep19-4LF inhibit Streptococcus mutans growth and biofilm formation. Microb Pathog. 2019 Aug;133:103546.